

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)**

Ms. Nancy Sander

**Committees:** Joint Nonprescription Drugs Advisory Committee and Pulmonary-Allergy Drug Advisory Committee Meeting

**Meeting Date:** January 24, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to discussions of the continued need for the designation of over-the-counter (OTC) epinephrine-metered dose inhalers (MDIs) for the treatment of asthma as an essential use of ozone-depleting substances under 21 CFR 2.125, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Stock	Affected Company	Valued between \$25,001 to \$50,000
Advisory Board unrelated to the topics to be discussed.	Affected Company	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

\_\_\_\_\_  
Signature of SGE

1/4/05

\_\_\_\_\_  
Date